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Abstract Antibodies directed against a peptide corresponding 
to the second loop of the human j3z-adrenergic receptor were 
induced in rabbits by immunisation with the free peptide in 
complete Freund’s adjuvant. The resulting antibodies were 
affinity-purified and shown to be monospecific for the target 
receptor. They were able to stimulate the L-type Ca*+ channels 
in whole-cell patch-clamp experiments on isolated adult guinea- 
pig cardiomyocytes. This effect was similar to that obtained by 
the specific fit-adrenergic agonist zinterol. The antibody effects 
could be blocked with the specific b-adrenergic inverse agonist 
ICI118,551 but not with the neutral antagonist alprenolol. These 
results suggest that the antibodies recognise the active conformer 
of the b-adrenergic receptor. 
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1. Introduction 
Increasing evidence suggests that G protein-coupled recep- 
tors can be found in two different conformational states: a 
‘resting’ and an ‘active’ state both of which are in equilibrium. 
This hypothesis, based on the existence of ‘constitutively ac- 
tive’ mutated receptors [I] and on the pharmacological prop- 
erties of receptors, hyperexpressed in transfected cells [2,3] or 
in transgenic animals [4], could explain the activation of the 
effector systems of these receptors in the ‘unliganded’ state [5- 
8]. Several observations, on the other hand, suggest that anti- 
bodies or autoantibodies directed against the second extracel- 
lular loop of G protein-coupled receptors are able to induce 
‘agonist-like’ activities by an until now unknown mechanism 
[9,10]. We here report the stimulation of L-type Ca2+ channels 
in isolated guinea-pig cardiomyocytes by anti-peptide antibod- 
ies against the second extracellular loop of the /32-adrenergic 
receptor. The pharmacological properties of these antibodies 
suggest that they act by stabilising the ‘active’ state of the 
receptor. 
2. Materials and methods 
2.1. Antibody production, p@ication and characterisation 
Rabbits were immunised with the C-terminal cysteinylated H26Q 
peptide (see Table 1) derived from the human Pz-adrenergic receptor 
as free peptide and the anti-peptide antibodies affinity purified as 
previously described [1 11. The concentration of the purified antibodies 
was calculated from the absorbance at 280 nm (1.45 corresponding to 
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1 mg/ml). The enzyme immunoassay consisted of a double-sandwich 
method in which the second antibody is a biotinylated goat anti-rab- 
bit IgG(H+L) from Jackson Laboratories and the revelator a strepta- 
vidin-peroxydase conjugate. The substrate was HzOz-ABTS [1 11. The 
specificity of the response was assayed using the H26Q and H26R 
peptide derived from the human PI-adrenergic receptor (Table 1). 
2.2. Immunoblotting of the receptor 
Murine LB cells transfected with the human Pz-adrenoceptor gene 
(a kind gift of Dr. M. Viguier, Institut Cochin de GBn&ique Mol&cu- 
laire, Paris) were grown under standard conditions in the presence of 
600 &ml geneticin. The level of expression corresponded to 301&400 
fmol/mg membrane protein. Membranes were prepared after resus- 
pension of serum-starved cells in 50 mM TRIS-HCl and 2.5 mM 
MgClz at pH 7.4 and disruption by homogenation in a Polytron. 
Debris was centrifuged for 15 min at 3000Xg and the membranes 
precipitated by centrifugation for 45 min at 22000Xg. The pellet 
was resuspended in the disruption buffer. 
Membrane proteins were separated by electrophoresis in a 10% 
polyacrylamide gel after denaturation and reduction in sodium dode- 
cyl sulfate and mercaptoethanol according to Laemmli [12]. The pro- 
teins were transferred on nitrocellulose under standard conditions 
[13]. After saturation of the nitrocellulose with phosphate-buffered 
saline (PBS), pH 7.4, containing 5% skimmed milk powder, 0.1% 
Tween-20 overnight at 4”C, strips were incubated for 2 h at 37°C 
with 3 nM purified anti-peptide antibody pre-incubated, or not, for 
1 h with 6 PM peptide. Strips were washed, incubated for 1 h with 
donkey anti-rabbit F(ab)z antibody-peroxidase conjugate (Jackson 
Laboratories, USA) diluted lOOO-fold in blocking buffer. The strips 
were washed 3 times in PBS containing 0.1% Tween-20 and immuno- 
complexes revealed using the enhanced chemiluminescence procedure 
(ECL on Hyperfilm, Amersham, UK). 
2.3. Electrophysiological measurements 
Cardiomyocytes were isolated using a collagenase/protease diges- 
tion technique described elsewhere [14]. Dissociated cells were placed 
in a 1 ml chamber on the stage of an inverted microscope (Nikon, 
Diaphot 300, Japan). The chamber was continuously perfused at a 
rate of 1 ml/min with Tyrode’s normal solution. The composition of 
this solution was (in mM): NaCl, 140; KCl, 5.4; N-2-hydroxy-ethyl- 
piperazine-N’-2-ethanesulfonic acid (HEPES), 10; CaC12, 1.8; MgC12, 
1: NaH2P04, 0.33; and glucose, 11. The pH was 7.3. 
Whole-cell voltage-clamp experiments were done in these isolated 
single cells at room temperature (22-25’(Z). During the experiments, 
cells were locally superfused with an extracellular solution containing 
(in mM): tetraethylammonium chloride (TEACl), 140; CsCl, 6; 
HEPES, 10; CaCl2, 1.8; MgCl2, 1; and glucose, 10. The pH was 
adjusted to 7.3 with TEAOH. This solution was superfused at a 
rate of 1 ml/min. All drug and antibody solutions were prepared daily 
and diluted as desired in the extracellular solution. The patch pipettes 
(24 Ma) were fabricated with borosilicate glass. Pipettes were filled 
with (in mM): CsCl, 130; HEPES, 11; EGTA ethylene glycol-bis (p- 
aminoethylether)-N,N,N’,N’-tetraacetic acid), 10; TRIS-GTP, 1; and 
Mg2+-ATP, 5. The pH was adjusted to 7.3 with CsOH. After the 
formation of a gigaseal (4-10 GR) between the cell membrane and 
the pipette and rupturing of the membrane patch, whole-cell L-type 
Ca2+ currents (Ica) were elicited by 500 ms voltage steps applied from 
a holding potential of -80 mV to +10 mV every 7 s. 
Cell capacity (proportional to cell size) was measured by integration 
of the current elicited by a 10 mV, 20 ms pulse and this value was 
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used to evaluate Ica density (pA/pF). Currents were recorded using a 
RK300 Patch and Cell Clamp amplifier (Biologic, Meylan, France) 
connected to a PC 486 computer, which was equipped with pClamp 
software (version 6.0.2, Axon Instruments). The currents were stored 
in the computer for subsequent analysis with pClamp software. The 
calcium currents were measured as the difference between inward peak 
current and the current at the end of the depolarisation pulse. 
3. Results and discussion 
Taking advantage of the existence of a T-cell epitope in the 
sequence corresponding to the second extracellular loop of the 
human Pz-adrenergic receptors [15], we were able to obtain 
high titers of anti-peptide antibodies in rabbits and to affinity- 
purify these antibodies on a CNBr-Sepharose activated pep- 
tide column as previously described [l 11. The antibodies were 
monospecific for the Pz-adrenergic receptor peptide since no 
cross-reaction could be shown on the correponding sequence 
of the PI-adrenergic receptor (Fig. 1). As shown previously 
[l 11, the antibodies were able to detect the receptor by immu- 
noblotting in a specific manner as assessed by inhibition ex- 
periments with the antigenic peptide (Fig. 2). In view of the 
high conservation of this domain in the rodent species, whose 
receptor sequence is known (Table l), it was considered that 
antibodies cross-reactive against the guinea-pig receptor, 
whose sequence is as yet unknown, was very likely. 
: 
RaH26Q nM 
Fig. 1. Immunochemical specificity of the affinity-purified antibodies 
against the second extracellular loop of the human Pz-adrenergic re- 
ceptor (RaH26Q). Absorbance values are given for the enzyme im- 
munoassay against the peptide corresponding to the Pz-adrenergic 
receptor (amino acids 172-197) [28] (0-0) and that corresponding 
to the P1-adrenergic receptor (amino acids 197-222) [32] (H) as 
shown in Table 1. 
To study the stimulating activity of the anti-peptide anti- 
bodies on the Pz-adrenergic receptor, the whole-cell patch- 
clamp technique on guinea-pig cardiomyocytes was used to 
assess the influx of Ca2+ ions by L-type calcium channels 
(I&, which is known to be stimulated by CAMP dependent 
mechanisms, induced by stimulation of the P-adrenergic re- 
ceptors [16]. Since, the P-adrenergic system of guinea-pig car- 
diomyocytes is primarily of the P1-subtype [17], the activation 
of the Ca2+ channel by a specific Pz-selective partial agonist, 
zinterol [18] was assayed to quantify the contribution of the 
P2-adrenergic receptors. The increase in ZQ was 14% of that 
obtained with the non-subtype specific agonist isoproterenol 
(Fig. 3 and Table 2). This result corresponds to that known 
about the Pz-adrenergic component in guinea-pig cardiomyo- 
cytes [17]. 
antibody was shown by the blocking effect of the Pz-selective 
inverse agonist, ICI1 18,551 [2]. When the non-subtype specific 
neutral antagonist alprenolol [2,3] was added under the same 
conditions, the stimulation of Zca by the anti-peptide antibod- 
ies was not inhibited but increased significantly (Fig. 4 and 
Table 2). This is not due to the different dissociation rates of 
the antagonists, since propranolol and alprenolol have similar 
binding kinetics [19]. Neither the addition of the Pz-selective 
partial agonist zinterol had an effect after activation of the 
receptor by the anti-peptide antibodies nor the anti-peptide 
antibody after activation by the Pz-specific partial agonist, 
zinterol. 
When the affinity-purified anti-peptide antibodies were 
added to the incubation medium of the cardiomyocytes, an 
increase in Zca similar to that induced by zinterol was ob- 
served. Presaturating the antibody with the immunogenic pep- 
tide completely blocked this response, confirming that the 
antibody activity was mediated by the antibody combining 
sites. The P-adrenergic antagonist, propranolol, added at the 
same time as the antibody completely blocked its effect, con- 
firming that the enhancement of Zca was mediated by the p- 
adrenergic receptor. The subtype specificity of the anti-peptide 
These results can be explained by the hypothesis that the 
anti-peptide antibodies recognise an epitope which is present 
on the ‘activated’ state of the receptor. Since the two-state 
receptor hypothesis states that the receptor in the unliganded 
state is in equilibrium between the ‘resting’ and ‘active’ con- 
formers, the stimulating effect of the antibodies are to be 
interpreted as a recognition of the unliganded ‘active’ confor- 
mer. The existence of unliganded ‘active’ receptor conformers 
in guinea-pig and human cardiomyocytes is suggested by the 
existence of calcium current activation by empty P-adrenocep- 
tors [7]. The Pz-selective inverse agonist, shifting the receptor 
to the ‘resting’ conformation, makes the epitope recognised by 
the anti-peptide antibody inaccessible and the functional effect 
Table 1 
Comparison of the sequence of the second extracellular loop of the human Pz-adrenoceptor to show the high homology conserved over the dif- 
ferent species and the hifferences with the human PI-adrenoceptor 
Suecies Subtvoe Seauence 
1 
Human 1281 
<. 
!.%- H-W-Y-R-A-T-H-Q-E-A-I-N-C-Y-A-N-E-T-C-C-D-F-F-T-N-Q 
Mouse [is]* 
. - 
H-W-Y-R-A-T-H-K-K-A-I-D-C-Y-T-E-E-T-C-C-D-F-F-T-N-Q 
Hamster [30] ;;: H-W-Y-R-A-T-H-~-R-A-I-~-C-Y-H-R-E-T-C-C-D-F-F-T-N-Q 
Rat [31] 
Human [32] ;;: 
H-W-Y-R-A-T-H-K-~-A-I-~-C-Y-~-~-E-T-C-C-D-F-F-T-N-Q 
H-W-W-R-A-E-S-a-E-A-~-~-C-Y-N-B_P-K-C-C-D-F-~-T-N-~ ---- -- 
Conserved mutations are underlined, non-conserved mutations are bold and underlined. 
The numbers in brackets correspond to the references. 
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Fig. 2. Immunoblot of the human receptor from membranes of 
mouse LB cells transfected with the human receptor gene. (-) Incu- 
bation with 3 nM purified anti-H26Q antibody; (+) incubation with 
3 nM purified anti-H26Q antibody in the presence of 6 pM H26Q 
peptide. 
of the latter disappears. It is worthwhile to note in this con- 
text that human autoantibodies directed against the second 
extracellular loop of the Pi-adrenergic receptor do not immu- 
noprecipitate the antagonist-receptor complex [20]. The neu- 
tral antagonist, alprenolol, does not change the receptor con- 
formational equilibrium enabling the anti-peptide antibodies 
to recognise the active ‘conformer’ and exert their activating 
effect on the Ca2+ channels. The increase in Ioa induced by 
the anti-peptide antibodies in the presence of alprenolol com- 
pared to that induced by the antibodies alone, could be as- 
cribed to an intrinsic agonist effect of the latter. The antibod- 
ies, by stabilising the ‘active’ conformation, can shift the 
equilibrium towards the ‘active’ state. 
Finally, the total inhibition by propranolol of the anti-pep- 
tide antibody induced increase in Ioa suggests that this agent 
has an inverse agonist activity. Conflicting results have been 
obtained concerning the ‘inverse agonist’ potency of propra- 
nolo1 [2,3]. The results presented here suggest that, for a cell 
expressing the receptor under normal condtions, it can be 
considered an inverse agonist. 
The ‘two-state’ receptor model has been hypothesized from 
results obtained in mutated ‘constitutively’ active receptors 
[l], and from studies on agonist-independent stimulation of 
receptors [5-S]. The first immunological evidence for this 
model in normal cardiomyocytes is presented here. It empha- 
Table 2 
Statistical analysis of patch-clamp data: effects of the direct applica- 
tion of different drugs and anti-peptide antibody upon Zo, 
Drug ka 
(% of control) 
Isoproterenol (100 nM) 
Zinterol (10 nM) 
RaH26Q (3 nM) 
RaH26Q (3 nM)+H26Q (15 uM) 
RaH26Q (3 nM)+Propranolol (5 pM) 
RaH26Q (3 nM)+ICI118,551 (10 nM) 
RaH26Q (3 nM)+Alprenolol (10 pM) 
Zinterol (10 nM) after RaH26Q (3 nM) 
RaH26Q (3 nM) after Zinterol (10 nM) 
129+51 
18+ 4 
20f 3 
- 10f 5 
- 8f 3 
- llf 1 
282 3 
21f 2 
26f 8 
“Mean + SD. 
bNumber of cells tested. 
sizes the importance of the second extracellular loop in the 
equilibrium between the two states of G protein-coupled re- 
ceptors as was already inferred from point mutation studies 
[21] and recently confirmed by the production of a constitu- 
tively active thrombin receptor after chimeric substitutions in 
this region of the receptor [22]. Immunological studies confirm 
that the main epitopic target of functional autoantibodies on 
G protein-coupled receptors are also localised at the second 
extracellular loop [9], suggesting that these antibodies act by 
influencing the ‘conformer’ equilibrium. The accumulating 
evidence that oligomers of G protein-coupled receptors could 
reflect the active state of these receptors [23] suggests that 
antibodies directed against specific extracellular epitopes 
could stabilise at least the dimeric form. 
If these autoantibodies are pathologically important, in- 
verse agonists should be the drugs of choice to block their 
pathogenic effects. The beneficial effects of some pr-selective 
antagonists in idiopathic cardiomyopathy [24], a disease in 
which autoantibodies directed against the second extracellular 
loop of the PI-adrenergic receptor have been observed [25-271, 
could be due to the inverse agonist properties of the drugs 
used. 
Finally, anti-peptide antibodies ‘sensitive’ to one of the con- 
formers are new pharmacological tools to distinguish between 
COlltrol Zinterol(O.01 pM) 
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Fig. 3. Effect of agonists on calcium current (Ior,) of ventricular gui- 
nea-pig cardiomyocytes. A: (upper part) Traces of calcium currents 
recorded from the same cell under control conditions (a) and 2.5 
min after 0.01 pM zinterol application (b) dotted line: zero current. 
(lower part) Time course of Ica density in the same cell before and 
after application of zinterol (0.01 PM). B. (upper part) Traces of 
calcium currents recorded from the same cell under control condi- 
tions (a) and after application of isoproterenol (1 PM). (lower part) 
Time course of Zca density under control conditions and after appli- 
cation of isoproterenol (1 PM). 
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Control RaH26Q (3 nM) 
-3 1 
I I I 
1 2 3 
Control ICI 116,551 (0.01 pM) + RaH26Q (3 nM) 
Alprenolol(l0 PM) + RaH26Q (3 nM) 
Time (min) 
Fig. 4. Effects of anti-peptide antibody RaH26Q on calcium cur- 
rents (I& of ventricular guinea-pig cardiomyocytes. A: (upper part) 
Traces of calcium currents recorded from the same cell undercon- 
trol conditions (a) and 2.3 min after 3 nM RaH26Q application (b); 
dotted line: zero current. (lower part) Time course of Zoa density in 
the same cell before and after application of anti-peptide RaH26Q 
(3 nM) showing an increase of this current. B: Time course of ZC, 
density under control conditions and after application of RaH26Q 
(3 nM) and ICI118,551 (10 nM). The antibody effect is completely 
abolished. C: Modification of the time course of Zch density by sim- 
ultaneous application of RaH26Q (3 nM) and alprenolol (10 PM). 
The effect of the antibody is increased (for statistical analysis of the 
results, see Table 2). 
neutral antagonists and inverse agonists for the different G 
protein-coupled receptors. 
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